Drug
Buprenorphine
Buprenorphine: highest development phase Post-Market, developed by Chiesi Farmaceutici, Hikma, Indivior and others. 9 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Chiesi Farmaceutici, Hikma, Indivior
Trials
| Drug | Phase | Indication |
|---|---|---|
| buprenorphine NCT00684073 | Post-Market | Opiate-related Disorders |
| buprenorphine NCT00279565 | Post-Market | Hepatitis C, Chronic |
| Buprenorphine Extended-Release Injection NCT05704543 | Post-Market | Opioid Use Disorder |
| BUPRENORPHINE | Approved | |
| BUPRENORPHINE AND NALOXONE | Approved | |
| BUPRENORPHINE | Approved | |
| BUPRENORPHINE | Approved | |
| Buprenorphine NCT02044094 | Phase 2 | Opioid Use Disorder |
| Buprenorphine NCT03608696 | Phase 1/2 | Neonatal Abstinence Syndrome |
Latest
- Boxed warning added: BUPRENORPHINE
- Boxed warning added: BUPRENORPHINE
- Boxed warning added: BUPRENORPHINE
- Label updated: BUPRENORPHINE AND NALOXONE
Follow Buprenorphine on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.